Market news — every asset we track

Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in revenue and $80 million to $100 million in Adjusted EBITDA (a non-GAAP measure)VEVYE® delivered quarterly revenue of $29.4 million, up approximately 40% sequentially and approximately 58% year over year, with continued prescription, prescriber, and market-share growthVEVYE secured an

Aug 10finance.yahoo.com

HROW

Samsung Bioepis, Harrow present SB11 biosimilar study results

Jul 20Investing.com

HROW

Harrow presents studies on eye care products at medical meeting

Jul 20Investing.com

HROW

Harrow: Debt-Fueled Liquidity Masks An Operating Cash Problem (NASDAQ:HROW)

Jul 15Seeking Alpha

HROW

This is the newest page. Registered accounts read further back.